Can(Ted) Dong

-Invested by BI Ventures, Viva, etc. -ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state-of-the-art technologies and novel strategies.

-Co-lead by Viva, Broadview Ventures, Rev1. -Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect.

-Co-lead by Viva, Co-Win Ventures, Sinovation Ventures. -Through its unique single-cell discovery platform, Amberstone develops immunotherapies that are conditionally activated at the tumor microenvironment.

-The corporate venture arm of Viva Biotech Holdings(01873. HK). -Focus on early-stage incubation/investment in the healthcare sector (Seed-A round), 350+ companies reviewed, 5 companies invested, 10+ companies under post-investment management. -Led a 3-person team, including 2 PhDs and 1 finance colleague with 300+ companies reviewed.

-Focus on equity investment in IVD, medical devices, and biotechnology, 120 projects reviewed

National Scholarship, Chairman of the Student Union

National Scholarship, Outstanding Graduate